<DOC>
	<DOCNO>NCT00628043</DOCNO>
	<brief_summary>This study investigate clinical efficacy safety epoetin beta 36,000 IU compare placebo administrate subcutaneously ( s.c. ) once-weekly 12 week anemic patient lung cancer gynecologic cancer undergo chemotherapy .</brief_summary>
	<brief_title>Clinical Study Epoetin Beta Chemotherapy-Induced Anemia ( CIA ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Lung cancer gynecologic cancer patient Undergoing platinumbased chemotherapy repeat ≧ 2 cycle erythropoietin ( EPO ) placebo administration 8.0 g/dL ≦ hemoglobin concentration ( Hb ) ≦ 10.0 g/dL 20 79 year old Performance status : 0 2 No iron deficiency anemia Red blood cell transfusion within 4 week treatment Erythropoietin therapy within 8 week treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>patient</keyword>
	<keyword />
	<keyword>chemotherapy</keyword>
	<keyword>induced</keyword>
	<keyword>anemia</keyword>
</DOC>